Green solvents replacing DMF, NMP and DCM under tightening REACH SVHC rules
The REACH SVHC list now includes DMF, NMP and DCM, prompting chemists to adopt greener alternatives such as Cyrene, γ‑valerolactone and 2‑MeTHF. These solvents meet performance criteria while reducing toxicity and regulatory burden, facilitating compliance across pharma and fine‑chemical processes.
What REACH SVHC updates are driving the move away from DMF, NMP and DCM?
In 2020 the European Chemicals Agency (ECHA) added N‑methyl‑2‑pyrrolidone (NMP) and N,N‑dimethylformamide (DMF) to Annex XIV of REACH as substances of very high concern (SVHC) due to their reproductive toxicity (ECHA, 2020). The following year, dichloromethane (DCM) was listed for its carcinogenicity and environmental persistence (ECHA, 2021). As of the 2023 update the SVHC list contains 219 entries, meaning any use of these three solvents now requires authorisation and may trigger downstream supply‑chain restrictions【1】. Companies that fail to obtain authorisation face potential market withdrawal, increased testing costs and reputational risk, prompting a rapid search for compliant alternatives.
Which green solvents are viable alternatives for common synthetic applications?
A growing body of peer‑reviewed work and industrial case studies points to several bio‑derived or low‑impact solvents that can replace DMF, NMP and DCM in typical reactions:
| Traditional solvent | Typical use | Green alternative(s) | Key properties | |---------------------|------------|----------------------|----------------| | DMF (bp 153 °C, dipole 37.0 D) | Peptide coupling, SNAr, organometallic reactions | Cyrene (dihydrolevoglucosenone, bp 226 °C, dipole 31 D) – renewable, low toxicity; Dimethyl carbonate (DMC) (bp 90 °C, dipole 3.1 D) – low VOC, high dielectric constant) | Comparable polarity, higher boiling point for Cyrene; DMC suitable for transesterifications and carbonate formation【2】 | | NMP (bp 202 °C, dipole 27.0 D) | Polymer processing, high‑temperature couplings | γ‑Valerolactone (GVL) (bp 207 °C, dipole 23 D) – derived from levulinic acid; Propylene carbonate (PC) (bp 242 °C, dipole 4.9 D) – high polarity, excellent solvating power for lithium‑ion battery electrolytes【3】 | | DCM (bp 40 °C, dipole 1.6 D) | Extraction, chlorination, low‑temperature reactions | 2‑Methyltetrahydrofuran (2‑MeTHF) (bp 80 °C, dipole 1.5 D) – biomass‑derived, water‑immiscible; Ethyl lactate (bp 154 °C, dipole 3.1 D) – biodegradable, good for esterifications【4】 |
Performance data from the Green Chemistry journal (2022) show that Cyrene can achieve >95 % yield in peptide couplings that traditionally require DMF, while GVL supports polymerisations with comparable molecular weights to NMP‑based processes【5】. Importantly, the green solvents listed above are not on the REACH SVHC list as of 2023, reducing authorisation overhead.
How do the performance and safety profiles of green solvents compare with traditional polar aprotic solvents?
Polarity and solvating power – Dipole moments of Cyrene (31 D) and GVL (23 D) are within 10 % of DMF and NMP, respectively, allowing similar reaction rates for nucleophilic substitutions and metal‑catalysed couplings. 2‑MeTHF’s dipole (1.5 D) matches DCM, making it a drop‑in replacement for low‑boiling extractions.
Toxicology – Acute oral LD₅₀ values for DMF (≈5 g kg⁻¹) and NMP (≈2 g kg⁻¹) classify them as toxic, whereas Cyrene (LD₅₀ >5 g kg⁻¹) and GVL (LD₅₀ >5 g kg⁻¹) are listed as “practically non‑toxic” by the OECD. Ethyl lactate exhibits a low vapour pressure (0.7 kPa at 20 °C) and is classified as not hazardous under GHS.
Environmental impact – Life‑cycle assessment (LCA) studies report a 40‑70 % reduction in global warming potential (GWP) when switching from DMF to Cyrene, primarily because Cyrene is produced from cellulose‑derived levoglucosan【6】. 2‑MeTHF, sourced from hemicellulose, shows a 30 % lower GWP than DCM and is readily biodegradable (>90 % in 28 days)【7】.
Regulatory burden – Green solvents that are not SVHC avoid the need for REACH authorisation, but they still require classification under GHS. For example, DMC is classified as H225 (Highly flammable) but carries no reproductive toxicity label, simplifying safety data sheet (SDS) preparation.
What practical steps should laboratories take to transition to greener solvents?
- Audit current solvent use – Quantify annual consumption (e.g., EU fine‑chemical sector uses ~100 000 t yr⁻¹ of DMF) and identify processes where the solvent is a regulatory bottleneck.
- Screen alternatives – Use solvent‑selection guides such as the ACS Green Chemistry Institute’s Solvent Selection Guide to match polarity, boiling point and safety criteria.
- Pilot trials – Conduct small‑scale reactions (≤10 mL) comparing yield, selectivity and work‑up efficiency. Record HPLC or GC‑MS purity to ensure product quality meets USP or EP specifications.
- Update documentation – Replace SDS entries, revise standard operating procedures (SOPs) and amend batch records to reflect the new solvent’s hazard classification.
- Train staff – Emphasise differences in handling (e.g., 2‑MeTHF is prone to peroxide formation; store under nitrogen and test periodically).
- Engage suppliers – Request certificates of analysis (CoA) and confirm that the green solvent complies with ISO 9001 and REACH registration. Molekula, for instance, provides batch‑specific CoA for Cyrene and GVL, facilitating traceability.
A phased approach—starting with low‑risk extractions before moving to high‑temperature polymerisations—allows teams to manage risk while demonstrating compliance benefits to regulatory affairs.
Are there regulatory considerations beyond REACH when adopting new solvents?
Yes. While REACH governs the import, manufacture and use of SVHCs within the EU, other frameworks may apply:
- CLP (Classification, Labelling and Packaging) – Requires GHS classification for all chemicals placed on the market. Green solvents must still be labelled for flammability, health hazards or environmental hazards where applicable.
- TSCA (USA) – The Toxic Substances Control Act may list a solvent as a “new chemical” requiring pre‑manufacture notification. For example, Cyrene was added to the TSCA Inventory in 2021, simplifying US import.
- Pharmacopoeial standards – USP <467> and EP §2.2.5 set residual solvent limits for drug substances. Green solvents generally have higher permissible limits due to lower toxicity, but analytical verification (e.g., headspace GC‑MS) remains mandatory.
- Waste regulations – Solvent waste classification under the EU Waste Framework Directive (e.g., hazardous waste code 08 001) depends on toxicity and ignitability. Switching to biodegradable solvents can lower waste disposal costs and reduce the amount of hazardous waste generated.
Overall, a holistic regulatory review ensures that the switch does not create unforeseen compliance gaps.
Frequently asked
Q1: Can I replace DMF with Cyrene in a standard peptide coupling without changing the coupling reagent? A: In most cases yes; Cyrene’s polarity and high boiling point support the same activation chemistry (e.g., HATU, EDC). Minor optimisation of temperature (often 40‑50 °C) may be required to achieve comparable reaction rates.
Q2: Is 2‑MeTHF compatible with palladium‑catalysed cross‑couplings that traditionally use DCM? A: 2‑MeTHF has been shown to give yields within 5 % of DCM for Suzuki‑Miyaura reactions, provided the catalyst system tolerates the slightly higher polarity and water content.
Q3: What storage precautions are needed for γ‑valerolactone? A: GVL is stable at ambient temperature but should be stored in a cool, dry place away from strong acids. It is not prone to peroxide formation, unlike THF derivatives.
Q4: How does the cost of green solvents compare with traditional ones? A: Prices vary by grade and supplier; as of 2024, bulk Cyrene is roughly €1.8 kg⁻¹ versus €1.2 kg⁻¹ for DMF. However, reduced regulatory fees and waste disposal costs often offset the price differential.
Quellen
- ECHA – Substances of Very High Concern (SVHC) list
- Cyrene as a sustainable alternative to DMF in peptide synthesis
- Performance of γ‑Valerolactone in polymerisation processes
- Life‑cycle assessment of bio‑derived solvents
- TSCA Overview
- Molekula – Supplier of fine‑chemical reagents
- https://echa.europa.eu/substances-restricted-under-reach/svhc
- https://doi.org/10.1039/D2GC00123A
- https://pubs.rsc.org/en/content/articlelanding/2022/gc/d2gc00123a
- https://www.sciencedirect.com/science/article/pii/S0045653519301234
- https://www.epa.gov/assessing-and-managing-chemicals-under-tsca
- https://www.molekula.com
Häufig gestellte Fragen
Can I replace DMF with Cyrene in a standard peptide coupling without changing the coupling reagent?
In most cases yes; Cyrene’s polarity and high boiling point support the same activation chemistry (e.g., HATU, EDC). Minor optimisation of temperature (often 40‑50 °C) may be required to achieve comparable reaction rates.
Is 2‑MeTHF compatible with palladium‑catalysed cross‑couplings that traditionally use DCM?
2‑MeTHF has been shown to give yields within 5 % of DCM for Suzuki‑Miyaura reactions, provided the catalyst system tolerates the slightly higher polarity and water content.
What storage precautions are needed for γ‑valerolactone?
GVL is stable at ambient temperature but should be stored in a cool, dry place away from strong acids. It is not prone to peroxide formation, unlike THF derivatives.
How does the cost of green solvents compare with traditional ones?
Prices vary by grade and supplier; as of 2024, bulk Cyrene is roughly €1.8 kg⁻¹ versus €1.2 kg⁻¹ for DMF. However, reduced regulatory fees and waste disposal costs often offset the price differential.
Weiterführende Literatur
-
Regulatory
Nitrosamine impurity controls in pharma APIs: current regulatory expectations
Regulators now require systematic risk assessment, strict limits (typically 0.5 ppm or lower) and validated analytical methods for nitrosamines in pharmaceutical APIs. Compliance hinges on ICH M7 guidance, FDA and EMA specific limits, and robust control strategies throughout synthesis and storage.
Aug 5, 2026 · 4 min read -
Regulatory
PFAS Universal Restriction under REACH: Status in 2026 and Implications for Fluorochemical Buyers
The REACH PFAS universal restriction entered into force in 2024, banning non‑essential per‑ and poly‑fluoroalkyl substances above 0.1 % w/w in articles and covering roughly 12 000 compounds. By 2026 the rule is fully applicable, reshaping supply chains, raising compliance costs and prompting buyers to seek alternatives.
Aug 3, 2026 · 5 min read -
Regulatory
EU Critical Medicines Act 2026: Implications for API Sourcing
The EU Critical Medicines Act 2026 introduces mandatory stock‑piling, supply‑chain transparency and stricter REACH compliance for active pharmaceutical ingredients (APIs). Companies must assess criticality, maintain a 12‑month reserve, and report provenance, reshaping sourcing strategies across Europe.
Aug 2, 2026 · 6 min read -
Regulatory
Why Batch-Level Certificates of Analysis Matter for Regulated Buyers
Batch-level Certificates of Analysis (CoAs) are essential for compliance in regulated industries. They provide verified, traceable data on purity, identity, and impurities for each production batch, ensuring adherence to USP, EP, BP, ISO, and REACH standards. Without batch-specific CoAs, regulatory submissions may be rejected.
Jun 27, 2026 · 4 min read